Cart
Products
<< Back to Chromatin Club Home Page
Boston Epigenetic Society (BES)
The Boston Epigenetic Society has been founded to:
- Promote epigenetics and epitranscriptomics
- Foster research connections between academics and industry epigenetics scientists
- Help promote new methods
- Create a support system for experimental epigenetics research
The Society brings together both academic and industry partners all sharing a passion for epigenetics. Founding members represent the following institutions and companies: Accent Therapeutics, Alkermes, Astellas Pharma, AstraZeneca, Constellation Pharmaceuticals, Ring Therapeutics, Sanofi, Beth Israel Deaconess Medical School, Broad Institute, Harvard Medical School, Harvard University, Massachusetts General Hospital, University of Massachusetts Medical School
For more information about the organization and events, please visit and join the BES LinkedIn Group.
Attendance is free of charge, but registration is required.
Upcoming Event Details
Date: September 21, 2023
Time: 9:00 a.m. (PT) / 12:00 p.m. (ET)
Topic: Biology of NSD2 and Clinical Opportunities for KTX-1001, the First NSD2 Inhibitor to Enter the Clinic
Featured Presenters:
- Terry Connolly, Ph.D. – CEO, K36 Therapeutics
- Or Gozani, M.D., Ph.D. – Dr. Morris Herzstein Professor of Biology, Stanford University
Previous Event Details
Date: May 18, 2023
Time: 9:00 a.m. (PT) / 12:00 p.m. (ET)
Featured Presenter:
- John Rinn, Ph.D. – Leslie Orgel Professor of RNA Science at University of Colorado, Boulder
The Role of lncRNAs in Transcriptional Regulation
